United States & Biogen
11 shared events · Importance 6 · Last updated Aug 05, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: Market where Leqembi Iqlik is now available; patients gain at-home treatment option.
Biogen: Joint development and commercialization partner for lecanemab; benefits from increased sales.
Aug 24, 2026 · 6 articles
Tech
United States: The United States has over 7 million Alzheimer's patients, highlighting the need for new treatments.
Biogen: Biogen's diranersen showed promising Phase II results, slowing cognitive decline by 26% in early Alzheimer's. The company plans a Phase III trial, positioning it as a leader in tau-targeting therapies.
Jul 14, 2026 · 22 articles
Business
United States: Leqembi is approved in the US; subcutaneous formulation approved as Leqembi Iqlik.
Biogen: Biogen is a partner in Leqembi commercialization; the sales results contribute to its Q2 2026 report.
Jul 29, 2026 · 6 articles
Business
United States: The merger is subject to US regulatory approvals and will create a US-based CNS-focused biopharma, impacting the domestic pharmaceutical landscape.
Biogen: Biogen is a commercial partner for Zurzuvae, sharing revenue with Supernus; the merger may affect this partnership.
Aug 03, 2026 · 6 articles
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
Biogen: Biogen was an early partner of Scribe, providing initial backing. While not directly involved in the IPO, the partnership highlights Scribe's early validation.
Jul 06, 2026 · 25 articles
Business
United States: The United States is the target market for Grey Matters Health Inc.'s expansion of neuroimaging clinics, addressing a growing demand for Alzheimer's detection and treatment within the country.
Biogen: Biogen, in collaboration with Eisai, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Business
United States: The United States is one of the countries where Leqembi is already approved; the India launch does not directly affect its market.
Biogen: Biogen collaborates with Eisai on Leqembi development and commercialization, benefiting from the India launch through co-commercialization.
Aug 03, 2026 · 6 articles
Business
United States: Country where Palsonify is approved and where most patients reside.
Biogen: Mentioned as comparison for premium paid in acquisitions.
Jul 06, 2026 · 34 articles
Tech
Biogen: Biogen produces lecanemab (Leqembi), an anti-amyloid drug whose efficacy was challenged by the Cochrane review, which could negatively affect its market performance.
Apr 16, 2026 · 6 articles
Business
Biogen: Biogen entered into a joint development and commercialization agreement for lecanemab with Eisai in 2014 and is involved in the AHEAD 3-45 clinical study.
May 15, 2026 · 6 articles
Business
Biogen: Biogen is a joint development and commercialization partner for Lecanemab, participating in clinical studies. While not the primary focus of this sales forecast, it benefits from the drug's success.
May 25, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Biogen interact across events, view sentiment trends, and discover connected entities.
Open Dashboard